Perspectives on the future of chronic myeloid leukemia treatment

Seminars in Hematology

Volumn 38, Issue 3 SUPPL. 8, 2001, Pages 35-42

  Appelbaum, Frederick R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA D ANTIGEN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

AGE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; PRIORITY JOURNAL; REVIEW; SIBLING;

EID: 0034861356     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90116-7     Document Type: Review

References (17)

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients
3. The German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
4. Interferon alpha versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
5. Interferon alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
6. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
7. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
8. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
9. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
10. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
11. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
12. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
13. Marrow transplantation for the treatment of chronic myelogenous leukemia
14. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
15. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome
16. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
17. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation